These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16299536)

  • 1. Development of transcriptionally regulated oncolytic adenoviruses.
    Ko D; Hawkins L; Yu DC
    Oncogene; 2005 Nov; 24(52):7763-74. PubMed ID: 16299536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic adenoviruses - selective retargeting to tumor cells.
    Mathis JM; Stoff-Khalili MA; Curiel DT
    Oncogene; 2005 Nov; 24(52):7775-91. PubMed ID: 16299537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectively replicating oncolytic adenoviruses as cancer therapeutics.
    Yu DC; Working P; Ando D
    Curr Opin Mol Ther; 2002 Oct; 4(5):435-43. PubMed ID: 12435044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
    Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
    J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers.
    Wildner O
    Curr Opin Mol Ther; 2003 Aug; 5(4):351-61. PubMed ID: 14513677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
    Palmer DH; Chen MJ; Searle PF; Kerr DJ; Young LS
    Gene Ther; 2005 Aug; 12(15):1187-97. PubMed ID: 15800660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
    Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K
    Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic (replication-competent) adenoviruses as anticancer agents.
    Toth K; Dhar D; Wold WS
    Expert Opin Biol Ther; 2010 Mar; 10(3):353-68. PubMed ID: 20132057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A demand for next-generation oncolytic adenoviruses.
    Hermiston T
    Curr Opin Mol Ther; 2006 Aug; 8(4):322-30. PubMed ID: 16955695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents.
    Rots MG; Elferink MG; Gommans WM; Oosterhuis D; Schalk JA; Curiel DT; Olinga P; Haisma HJ; Groothuis GM
    J Gene Med; 2006 Jan; 8(1):35-41. PubMed ID: 16044485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer selective adenoviruses.
    Alemany R
    Mol Aspects Med; 2007 Feb; 28(1):42-58. PubMed ID: 17300834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenoviral therapy for glioblastoma multiforme.
    Sonabend AM; Ulasov IV; Han Y; Lesniak MS
    Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.
    Lu Y
    Adv Drug Deliv Rev; 2009 Jul; 61(7-8):572-88. PubMed ID: 19393705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses.
    Working PK; Lin A; Borellini F
    Oncogene; 2005 Nov; 24(52):7792-801. PubMed ID: 16299538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication-selective oncolytic viruses in the treatment of cancer.
    Everts B; van der Poel HG
    Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
    J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.